TP53

Universal Cellular Machinery · DNA Damage Repair & Genomic Integrity

Why is p53 often described as a guardian of damaged cells?

TP53 makes p53, a regulator that responds to cellular damage by controlling gene activity and division. Its protective responses help stop damaged cells from continuing to multiply unchecked.

Common Gene Name
tumor protein p53
NCBI Gene ID
7157
Chromosome
17

Clinical Evidence Status

Actionability report availableEstablished disease relationshipTumor or drug-label biomarker context

These labels describe available evidence about a gene. They do not classify your variant or recommend a treatment.

Answer Sources

Explore supporting evidence (15 records)
Condition or drugEvidenceGrade / statusContextSource
Li-Fraumeni syndromeClinGen gene-disease validityDefinitiveAutosomal dominantView source
2024-03-22
Bladder cancerMedlinePlus related conditionAssociation type varies; no grade assigned hereView source
2020-02
Breast cancerMedlinePlus related conditionAssociation type varies; no grade assigned hereView source
2020-02
Head and neck squamous cell carcinomaMedlinePlus related conditionAssociation type varies; no grade assigned hereView source
2020-02
Ovarian cancerMedlinePlus related conditionAssociation type varies; no grade assigned hereView source
2020-02
Lung cancerMedlinePlus related conditionAssociation type varies; no grade assigned hereView source
2020-02
CholangiocarcinomaMedlinePlus related conditionAssociation type varies; no grade assigned hereView source
2020-02
Wilms tumorMedlinePlus related conditionAssociation type varies; no grade assigned hereView source
2020-02
MelanomaMedlinePlus related conditionAssociation type varies; no grade assigned hereView source
2020-02
Li-Fraumeni SyndromeClinGen clinical actionabilityScored report; not a validity gradeAdultView source
2024-03-24
Li-Fraumeni SyndromeClinGen clinical actionabilityScored report; not a validity gradePediatricView source
2024-03-24
Pirtobrutinib (5)FDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source
Venetoclax (3)FDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source
Zanubrutinib (3)FDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source
Acalabrutinib (4)FDA labeling biomarkerLabel mentions biomarker; actionability not inferredOncologyView source

Source snapshot: 2026-09-09. Consumer text updated: 2026-09-10. Source dates describe the cited records, not a new clinical review.

← Back to Universal Cellular Machinery